<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385268</url>
  </required_header>
  <id_info>
    <org_study_id>803895</org_study_id>
    <secondary_id>P60DA005186</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00385268</nct_id>
    <nct_alias>NCT00295451</nct_alias>
  </id_info>
  <brief_title>Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence</brief_title>
  <acronym>CAMPRAL</acronym>
  <official_title>A Phase II, Double-Blind, Placebo-controlled, Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to determine the safety, efficacy and tolerability of acamprosate for the treatment of&#xD;
      cocaine dependence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the trial is to evaluate the safety, tolerability and efficacy of&#xD;
      acamprosate for the treatment of 60 treatment seeking cocaine dependent outpatients. The&#xD;
      study will be an exploratory, double-blind, placebo-controlled 9-week trial, with a 2-cell&#xD;
      design (30 subjects per cell) in which either 1998 mg/day of acamprosate (666 mg TID) or&#xD;
      placebo will be given. Study medications will be given by medical practitioners, trained to&#xD;
      provide NIAAA's COMBINE Medical Management. In addition, patients will receive weekly&#xD;
      individual psychosocial treatment sessions utilizing Cognitive Behavioral Therapy (CBT) at&#xD;
      the University of Pennsylvania Treatment Research Center (TRC).&#xD;
&#xD;
      Primary Hypotheses:&#xD;
&#xD;
        1. Efficacy: Acamprosate-treated subjects will demonstrate less cocaine use during the&#xD;
           medication/placebo treatment phase, compared to placebo-treated subjects. Cocaine use&#xD;
           will be measured by self-report from the TLFB confirmed with urine assay for&#xD;
           benzoylecgonine (BE)&#xD;
&#xD;
        2. Safety and Tolerability: Acamprosate-treated subjects and placebo-treated subjects will&#xD;
           report similar rates of adverse events, assessed by weekly evaluations, physical exams&#xD;
           and laboratory testing.&#xD;
&#xD;
      Secondary Hypotheses:&#xD;
&#xD;
        1. Acamprosate-treated subjects, compared to placebo-treated subjects, will report less&#xD;
           craving for cocaine, measured by lower scores on the Brief Substance Craving Scale&#xD;
           (BSCS) (Somoza et al, 1995) and Multiple Choice Procedure (MCP) (Griffiths et al., 1993)&#xD;
           during the medication treatment phase.&#xD;
&#xD;
        2. Acamprosate-treated subjects, compared to placebo-treated subjects, will report fewer&#xD;
           withdrawal symptoms, measured by the Cocaine Selective Severity Assessment (Kampman et&#xD;
           al., 1998).&#xD;
&#xD;
        3. Acamprosate-treated subjects, compared to placebo-treated subjects, will report fewer&#xD;
           mood and anxiety symptoms, measured by the Hamilton Depression Rating Scale (HAM-D)&#xD;
           (Hamilton, 1967), Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1969), and Clinical&#xD;
           Global Impression Scale (CGI).&#xD;
&#xD;
        4. Subjects who are highly acamprosate-adherent (&gt;80% pills taken, verified by combining&#xD;
           patient report with blister cards) will have more cocaine non-use days during the&#xD;
           medication treatment phase, compared to those who are less acamprosate-adherent (&lt;80%&#xD;
           pills taken).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen</measure>
    <time_frame>8 weeks</time_frame>
    <description>cocaine abstinent weeks determined by all negative urine drug screens in each week (2 urine drug screens per week)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Active medication Acamprosate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1998mg/day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pills for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acamprosate</intervention_name>
    <description>1998 mg/dau fpr 8 weeks</description>
    <arm_group_label>Active medication Acamprosate</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male and females 18 years of age or older.&#xD;
&#xD;
          2. Subject meets DSM-IV criteria for current diagnose of cocaine dependence, determined&#xD;
             by The Structured Clinical Interview for DSM-IV (SCID-IV).&#xD;
&#xD;
          3. Subject used cocaine in the past 30 days totaling at least $200 worth of cocaine.&#xD;
             Cocaine use will be determined by utilizing the modified Timeline Followback,&#xD;
             crosschecked with the ASI, which inquires about dollar amounts spent on drug use.&#xD;
&#xD;
          4. Subject lives a commutable distance from the TRC and agrees to attend all research&#xD;
             visits, including follow-up visits.&#xD;
&#xD;
          5. Subject speaks, understands, and prints in English.&#xD;
&#xD;
          6. Written informed consent signed by the subject.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subjects mandated to treatment based upon a legal decision or as a condition of&#xD;
             employment.&#xD;
&#xD;
          2. Subjects with evidence of current substance dependence other than cocaine, alcohol or&#xD;
             nicotine dependence, as determined by the SCID-IV.&#xD;
&#xD;
          3. Subjects who meets DSM-IV criteria for current alcohol dependence who require a&#xD;
             medical alcohol detoxification.&#xD;
&#xD;
          4. Requires treatment with any psychoactive medications, including any anti-seizure&#xD;
             medications (with the exception of Benadryl used sparingly, if necessary, for sleep).&#xD;
&#xD;
          5. Has a lifetime DSM-IV diagnosis of bipolar affective disorder, schizophrenia or any&#xD;
             psychotic disorder, or organic mental disorder. Has current DSM-IV diagnosis of any&#xD;
             other clinically significant psychiatric disorder that will interfere with study&#xD;
             participation, as determined by the study physician or PI (Drs. Kyle Kampman, Charles&#xD;
             Dackis and Helen Pettinati).&#xD;
&#xD;
          6. Female subjects who are pregnant or lactating, or female subjects of childbearing&#xD;
             potential who are not using acceptable methods of birth control. Acceptable methods of&#xD;
             birth control include: barrier (diaphragm or condom) with spermicide, intrauterine&#xD;
             progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate&#xD;
             contraceptive injection, and oral contraceptives.&#xD;
&#xD;
          7. Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits&#xD;
             that are clinically unacceptable to the Principal Investigator. EKG-1st degree heart&#xD;
             block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes&#xD;
             are allowed; liver function tests [LFTs] &lt; 5 x ULN are acceptable. Eligibility will be&#xD;
             determined by most recent lab results collected prior to randomization.&#xD;
&#xD;
          8. Subjects with impaired renal function as indicated by corrected creatinine clearance&#xD;
             below 80 ml/min/70 kg as determined by the modified Cockcroft equation (Center for&#xD;
             Disease Control, 1986).&#xD;
&#xD;
          9. Subjects who have any disease of the gastrointestinal tract, liver or kidneys that&#xD;
             could result in a possibility of altered metabolism or excretion of the study drug. As&#xD;
             it is not possible to enumerate the many conditions which might impair absorption,&#xD;
             metabolism, or excretion, the investigators will be guided by evidence such as:&#xD;
             History of major gastrointestinal tract surgery (gastrectomy, gastrostomy, bowel&#xD;
             resection, etc) or a history of an active peptic ulcer or chronic disease of the GI&#xD;
             tract (ulcerative colitis, regional enteritis, or gastrointestinal bleeding).&#xD;
&#xD;
         10. History of significant heart disease (an arrhythmia which required medication, angina&#xD;
             pectoris, documented history of myocardial infarction, or heart failure).&#xD;
&#xD;
         11. Known hypersensitivity to acamprosate.&#xD;
&#xD;
         12. Subjects having participated in any investigational drug trial within 30 days prior to&#xD;
             randomizing into the study.&#xD;
&#xD;
         13. Subjects with any serious illnesses that may require hospitalization during the study,&#xD;
             as determined by the study physician or PI (Drs. Kyle Kampman, Charles Dackis and&#xD;
             Helen Pettinati).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Pettinati, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 6, 2006</study_first_submitted>
  <study_first_submitted_qc>October 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2006</study_first_posted>
  <results_first_submitted>August 28, 2013</results_first_submitted>
  <results_first_submitted_qc>November 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2013</results_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kyle Kampman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acamprosate</title>
          <description>1998mg/day for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
acamprosate : 1998 mg/dau fpr 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo pills for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
placebo : placebo pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acamprosate</title>
          <description>1998mg/day for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
acamprosate : 1998 mg/dau fpr 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo pills for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
placebo : placebo pills</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="8.8"/>
                    <measurement group_id="B2" value="46.1" spread="7.7"/>
                    <measurement group_id="B3" value="45.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen</title>
        <description>cocaine abstinent weeks determined by all negative urine drug screens in each week (2 urine drug screens per week)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>1998mg/day for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
acamprosate : 1998 mg/dau fpr 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pills for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
placebo : placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen</title>
          <description>cocaine abstinent weeks determined by all negative urine drug screens in each week (2 urine drug screens per week)</description>
          <units>cocaine abstinent weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.3"/>
                    <measurement group_id="O2" value="1.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>GEE model of repeated measures</method>
            <method_desc>GEE on repeated binary indicators of BE positive / negative test</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>5.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acamprosate</title>
          <description>1998mg/day for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
acamprosate : 1998 mg/dau fpr 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo pills for 8 weeks&#xD;
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.&#xD;
placebo : placebo pills</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Aches and Pains</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Helen Pettinati</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 139</phone>
      <email>helenp@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

